1.82
—
Close of 5 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Innocan Pharma
Its shares trade on Canadian Securities Exchange under the ticker INNO.CN. It has been listed since 24 September 2019. In the fiscal year to 31 December 2024, it reported revenue of $29.4m and a net loss of $1.8m. At that date it held total assets of $9.3m and shareholders' equity of $5.2m.
InnoCan Pharma Corp. operates as a pharmaceutical tech company. The company operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The firm is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Sept 2019
- Employees
- 7
- Website
- innocanpharma.com ↗
Leadership
Pay as last reported
- Mrs. Iris BincovichChairman of the Board, Chief Executive Officer, since 2019$401,000
- Mr. Yoram DruckerExecutive Vice President - Business Development, Director, Founder, since 2019$173,000
- Mr. Nelson HalpernChief Financial Officer$73,000
- Mr. Roni KamhiChief Operating Officer
- Mr. Nir AvramChief Technology Officer
- Mr. Peter BlochIndependent Director
- Mr. Ralph BossinoIndependent Director
- Mr. Eyal FlomIndependent Director, Corporate Secretary
- Mr. Joshua LinternIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- InnoCan Pharma Corp develops OTC topical treatments with cannabinoid administration technology.
- The company has a dedicated R&D segment for hydrogels containing liposomes for third parties.
- InnoCan operates in the Health Care sector with a focus on pharmaceutical tech innovation.
Weaknesses
- InnoCan Pharma Corp has only 7 employees, limiting operational capacity.
- The company's OTC product line is still under development, delaying market entry.
- InnoCan's R&D for non-pharmaceutical products lacks commercialization details.
Opportunities
- InnoCan's hydrogel technology for liposomes can be licensed to pharmaceutical corporations.
- The growing OTC market for cannabinoid-based treatments presents expansion potential.
- InnoCan's platform for targeted cannabinoid administration may attract third-party partnerships.
Threats
- InnoCan's reliance on third-party manufacturing for OTC products creates supply chain risks.
- The pharmaceutical industry faces regulatory challenges for cannabinoid-based treatments.
- Competition in the OTC market could impact InnoCan's future product adoption.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.